Banque Cantonale Vaudoise Increases Holdings in Insulet Corporation $PODD

Banque Cantonale Vaudoise lifted its holdings in Insulet Corporation (NASDAQ:PODD) by 68.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,870 shares of the medical instruments supplier’s stock after acquiring an additional 4,004 shares during the period. Banque Cantonale Vaudoise’s holdings in Insulet were worth $2,071,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. boosted its position in shares of Insulet by 64.2% during the first quarter. Assenagon Asset Management S.A. now owns 257,719 shares of the medical instruments supplier’s stock worth $54,080,000 after acquiring an additional 100,740 shares during the last quarter. Krilogy Financial LLC bought a new stake in shares of Insulet in the first quarter worth about $243,000. PKO Investment Management Joint Stock Co increased its holdings in shares of Insulet by 25.0% in the first quarter. PKO Investment Management Joint Stock Co now owns 1,000 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 200 shares during the last quarter. Brookstone Capital Management lifted its position in shares of Insulet by 39.3% in the first quarter. Brookstone Capital Management now owns 3,499 shares of the medical instruments supplier’s stock worth $734,000 after buying an additional 988 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Insulet by 712.1% in the first quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock worth $66,907,000 after buying an additional 279,587 shares in the last quarter.

Insulet Stock Up 2.9%

Shares of NASDAQ PODD opened at $158.25 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company has a market cap of $10.96 billion, a P/E ratio of 36.80, a PEG ratio of 1.07 and a beta of 1.13. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm has a 50-day simple moving average of $159.09 and a two-hundred day simple moving average of $220.64.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The company’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PODD shares. Deutsche Bank Aktiengesellschaft began coverage on Insulet in a research note on Tuesday. They set a “buy” rating and a $190.00 price target for the company. JPMorgan Chase & Co. lowered their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Citigroup lowered their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Oppenheimer cut their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, BTIG Research reduced their price target on shares of Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday, May 26th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $238.67.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.36% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.